Milestones

Since its founding in 1992, mse Pharmazeutika GmbH has been dedicated to Mitochondrial Medicine. An overview of the most important milestones:

1992–1999: Foundation and first products

  • 1992 – Founding of mse Pharmazeutika GmbH by Dr. Franz Enzmann and his wife Uta Enzmann in Bad Homburg
  • 1993 – Development of the MitoMed concept with its specific active ingredients (Mitoceuticals®) for the protection and activation of mitochondria, the “powerhouses of our cells”
  • 1994 – Publication of the first clinical study with an mse Q10 product: “The increase in the performance duration of endurance athletes correlates with the increase in Q10 plasma levels after Q10 intake”, G. P. Littarru, Energy and Defense
  • 1994 – Expansion of activities to the entire German-speaking region (DACH)
  • 1999 – Market launch of SanoMit® Q10, the first liquid ubiquinone Q10 product; Q10 is present in ultra-small droplets and can be absorbed by the body faster and approximately 4 times better than conventional Q10 in powder capsules

2000–2009: Clinical studies and growth

  • 2002–2008 – Publication of clinical studies:
    • “Complementary administration of Guttaquinon (liquid Q10) in inflammatory periodontal diseases”, K. Erler et al., special print from GZM – Praxis und Wissenschaft, 2002
    • “Coenzyme Q10 combined with mild hypothermia after cardiac arrest”, M. S. Damian et al., Circulation, 2004
    • “Influence of coenzyme Q10 and cerivastatin on the flow-mediated vasodilation of the brachial artery: results of the ENDOTACT study”, A. Kuettner et al., Int. J Cardiol., 2005
    • “Efficacy of coenzyme Q10 in migraine prophylaxis: A randomized controlled trial”, P. S. Sándor et al., Int. J Cardiol., 2005
    • “Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzym Q10 in parkinson disease”, A. Storch et al., Arch. Neurol., 2007
    • “Short-term effects of coenzyme Q10 in progressive supranuclear palsy: A randomized, placebo-controlled trial”, A. Stamelou et al., Mov. Disord., 2008
  • 2008 – mse continues to grow: Relocation to Nehringstraße in Bad Homburg
  • 2009 – Market launch of QuinoMit Q10® fluid; it contains ubiquinol, the active form of Q10, in ultra-small droplets and is absorbed twice as well as SanoMit® Q10
  • 2009 – Expansion of activities into Poland through the distribution partner “Mito-Pharma”

2010–2018: Research collaborations and awards

  • 2012 – Collaboration with Albstadt-Sigmaringen University on “Use of QuinoMit Q10® fluid in skin aging”, Prof. Dr. J. Bergemann
  • 2012 – Collaboration with the Institute of Neurophysiology at the University of Cologne on “Use of QuinoMit Q10® fluid in cardiac stem cell research”, Prof. Dr. Dr. J. Hescheler
  • 2013 – Expansion of activities into Taiwan through the distribution partner “Reformhaus”
  • 2014 – Expansion of activities into Sweden through the distribution partner “Tiwa Care”
  • 2015 – Use of QuinoMit Q10® fluid in intensive care medicine for patients with traumatic brain injury
  • 2016 – Product launch of the medicinal supplements (AEGS®) for accompanying nutritional support when taking cholesterol-lowering drugs (statins), antidiabetics (metformin), or oral contraceptives
  • 2016 – Publication of the clinical study “Accelerated Regeneration of ATP Level after Irradiation in Human Skin Fibroblasts by Coenzyme Q10”, D. Schniertshauer et al., Photochemistry and Photobiology
  • 2016 – IHK award for “Excellent Technology Transfer” in cooperation with Albstadt-Sigmaringen University, Prof. Dr. J. Bergemann
  • 2016 – Poster prize of the World Mitochondria Society at the 7th World Congress Targeting Mitochondria 2016
  • 2017 – Publication on “Observational study on skin care for atopic dermatitis – MythoSkin® Care Cream / Liposome Cream from mse Pharmazeutika”, Ästhetische Dermatologie
  • 2017 – Inclusion of our 2004 clinical study “Coenzyme Q10 combined with mild hypothermia after cardiac arrest” in the guidelines of the American Academy of Neurology
  • 2018 – Publication of the clinical study “Effect of liquid ubiquinol supplementation on glucose, lipids and antioxidant capacity in type 2 diabetes patients: a double-blind, randomised, placebo-controlled trial”, C.-H. Yen et al., British Journal of Nutrition

More about us: About mse · Dr. Franz Enzmann · Press articles